Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) provides an overview of immune approaches for the treatment of breast cancer at the 14th St. Gallen International Breast Cancer Conference 2015, including:
The prognostic influence of tumour-infiltrating lymphocytes;
Ongoing clinical trials of targeted therapies that modulate the immune system the PD-1 inhibitor, pembrolizumab, for triple-negative breast cancer, and the combination of trastuzumab and PD1-inhibitor for HER2-positive breast cancer;
Tumour antigen cancer vaccines and ductal carcinoma in situ (DCIS).
European Medical Journal